Menu
Wechat public account

Product Services

tcm development
Beijing CapitalBio Pharma Co., Ltd. (hereinafter referred to as "CapitalBio Pharma") is the industrial platform of CapitalBio Corporation dedicated to the advancement of traditional Chinese medicine (TCM). The Company pioneered the world's first large-scale precision screening model for TCM prescriptions, powered by life sciences and artificial intelligence. By leveraging digital technologies, CapitalBio Pharma empowers precision diagnostics and therapeutics, innovative TCM drug R&D, development of medicine-food homology products, and natural plant-based cosmetics, creating a new scientific pathway for the modernization and globalization of TCM.

CapitalBio Pharma has been accredited as a National High-Tech Enterprise, an Innovative SME, a Technology-Based SME, a Double-Soft-Certified Enterprise, an AAA-Rated Enterprise, and has established a Postdoctoral Research Station. In 2022, CapitalBio Pharma won the top prize at the National Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology, and was also recognized by the China Association of Chinese Medicine as one of the "Top 10 Academic Advances in Traditional Chinese Medicine" for that year. The Company holds 21 invention patents and 21 software copyrights. 
Molecular Compendium of Materia Medica (MCMM) Technology Platform

Studying Diseases and Traditional Chinese Medicine at the Molecular Level

All human cells contain the same set of genes (DNA), and differences in gene expression (RNA) determine the formation of different tissues and organs, as well as the development of various diseases. In ancient times, Shennong tasted hundreds of herbs and discovered the functions of TCM through human testing — a macroscopic, practice-based science. In contrast, the Molecular Compendium of Materia Medica (MCMM) technology studies the functions of TCM by examining its effects on intracellular gene expression — a microscopic, experiment-based science.



TCM Molecular Functional Experimental Database

Through eight years of experimental platform optimization and data accumulation, a large-scale molecular functional database of TCM has been established, containing 1 billion-level real-world gene expression data from 1,200 TCMs and foods on human cells, as well as over 30 million core functional signaling pathway data points.



"Multiple Bullets Hitting Multiple Targets" Intelligent Prescription Generation System

This system is driven by AI, targeting disease signaling pathways and leveraging drug-induced pathway reversal as its core mechanism. When disease pathway targets and pharmacodynamic pathway profiles are input into the computer, the traditionally manual process of prescription formulation — which previously required extensive consideration, trial, and error — is now automatically completed by the system through experimental data and computational algorithms, generating optimized TCM prescriptions.


Applications of Molecular Compendium of Materia Medica (MCMM) Technology

Precision Diagnostics: Pulmonary Health

This collaborative project applies MCMM technology to enable precision pulmonary health management. Through an integrated model combining traditional Chinese and Western medicine, it provides early and accurate diagnosis, precise conditioning, treatment, and management of lung health, integrated with health insurance — establishing a closed-loop system of precision diagnostics, treatment, and insurance coverage for pulmonary health. In the future, this approach will be expanded to cover a broader range of diseases, advancing personalized precision medicine that integrates TCM and Western medicine based on MCMM technology. This will contribute to the high-quality integration of TCM into the Belt and Road Initiative and accelerate the globalization of TCM.



Innovative TCM: Chronic Heart Failure Treatment

In collaboration with the team of Professor Wang Jie from Guang'anmen Hospital of the China Academy of Chinese Medical Sciences, this project starts from traditional classical theories and clinical experience, applying MCMM technology to develop a novel therapeutic agent for chronic heart failure. Clinical observations have demonstrated excellent efficacy in alleviating edema, wheezing, and fatigue, with an overall response rate exceeding 90%. Currently, randomized, double-blind, placebo-controlled clinical studies are being conducted at seven hospitals, including Guang'anmen Hospital (China Academy of Chinese Medical Sciences), Zhongshan Hospital (Fudan University), and West China Hospital (Sichuan University).



Medicine-Food Homology Products: Pulmonary Nodule Food Products
Data from medical examination institutions indicate that at least 30% of adults have pulmonary nodules. The Company has developed medicine-food homology conditioning products for high-risk pulmonary nodules and lung cancer supportive care, which are currently in the final stages of preparation for market launch.

Patent Application No.: ZL202310484715.8 — Zhuyu Rose Drink Solid Beverage




Natural Plant-Based Cosmetics: Hair Care Products

Addressing the significant market demand for anti-hair-loss products, the Company conducted drug screening using dermal papilla cells and screened over 600 TCMs, resulting in the development of the "Zhishan Formula" — a prescription that effectively promotes hair regeneration in both mice and humans. Raw material registration has been completed, packaging has been finalized, and the product is ready for market launch.


Product Registration No.: 京G妆网备字2023000319 — Yisiyifu Scalp Care Liquid

Industry Collaborations
CapitalBio Pharma collaborates on research projects with multiple renowned pharmaceutical companies, research institutions, and clinical hospitals.
The Company has signed strategic cooperation agreements with the China Geriatric Health Medicine Research Association and Beijing Tongrentang.
A cooperation agreement has been signed with China Resources SANJIU, focusing on screening of hospital preparations and intelligent prescription development.

Industry Influence
Xinhua News Agency Report: "Molecular Compendium of Materia Medica Technology: Using Modern Science to 'Retaste the Herbs'"
https://h.xinhuaxmt.com/vh512/share/11428764?d=134b0b2&channel=weixin
China Traditional Chinese Medicine News — Front Page Headline: "Exploring the Mysteries of Materia Medica in the Molecular World"
https://mp.weixin.qq.com/s/ZUHoQTEKk_iDOiCg14m-Kw
Angel investor Gong Hongjia invested RMB 40 million in CapitalBio Pharma.
The Company has laid out plans for marine drug development and engaged in in-depth exchanges with the Haikou Municipal Government to promote the growth of the marine pharmaceutical industry.
Collaborative innovation partnerships have been established with the Macao Centre for Chinese Medicine Research, facilitating cross-border industry-academia collaboration to advance the R&D and translation of innovative TCM.

Copyright © 2000-2023博奥生物集团有限公司 京ICP备14023013号-3

《互联网药品信息服务资格证书》: (京) - 非经营性-2016-0047 京公网安备11011402013114号